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The severe acute respiratory syndrome coronavirus (SARS-CoV) is highly pathogenic in humans, with a
death rate near 10%. This high pathogenicity suggests that SARS-CoV has developed mechanisms to overcome
the host innate immune response. It has now been determined that SARS-CoV open reading frame (ORF) 3b,
ORF 6, and N proteins antagonize interferon, a key component of the innate immune response. All three
proteins inhibit the expression of beta interferon (IFN-), and further examination revealed that these
SARS-CoV proteins inhibit a key protein necessary for the expression of IFN-, IRF-3. N protein dramatically
inhibited expression from an NF-B-responsive promoter. All three proteins were able to inhibit expression
from an interferon-stimulated response element (ISRE) promoter after infection with Sendai virus, while only
ORF 3b and ORF 6 proteins were able to inhibit expression from the ISRE promoter after treatment with
interferon. This indicates that N protein inhibits only the synthesis of interferon, while ORF 3b and ORF 6
proteins inhibit both interferon synthesis and signaling. ORF 6 protein, but not ORF 3b or N protein, inhibited
nuclear translocation but not phosphorylation of STAT1. Thus, it appears that these three interferon antag-
onists of SARS-CoV inhibit the interferon response by different mechanisms.
In 2003, severe acute respiratory syndrome coronavirus
(SARS-CoV) infected thousands of people throughout the
world, killing hundreds. The molecular mechanisms governing
virus-induced pathology have not been fully elucidated. The
first immune challenge a virus must surmount in order to cause
disease symptoms in people is the innate immune response. A
major component of innate immunity is the interferon re-
sponse. Infection of cells with virus causes the activation of
several cellular transcription factors, such as IRF-3 and NF-
B, which activate the expression of the interferon genes. Once
interferon is synthesized and released from cells, it binds to
interferon receptors, initiating a signaling cascade of the JAK/
STAT pathway that results in activated transcription factors
translocating to the nucleus. These transcription factors bind
to and activate genes containing an interferon-stimulated re-
sponse element (ISRE) in their promoters. Activation of these
genes enables the cell to combat the virus infection and can
prevent viral replication (8). Many viruses have developed
mechanisms to subvert the interferon response. Infection of
cells with SARS-CoV does not result in the production of
interferon, and pretreatment of cells with interferon prevents
growth of SARS-CoV (22, 33). These results indicate that
SARS-CoV has evolved to overcome the interferon response.
SARS-CoV contains a 29.7-kb single-stranded RNA ge-
nome wrapped in a helical nucleocapsid composed of multiple
copies of N protein, which in turn is surrounded by an envelope
containing a 180- to 190-kDa S glycoprotein, a 23-kDa M
glycoprotein, an 30-kDa 3a glycoprotein, and a small E pro-
tein. The viral gene order is similar to that in other known
coronaviruses, with the first two open reading frames (1a and
1b) encoding the viral replicase and the downstream mRNAs
encoding structural proteins S, E, M, and N. These genes are
interspaced with several accessory genes that are not essential
for in vitro or in vitro replication (open reading frames [ORFs]
3a, 3b, 6, 7a, 7b, 8a, 8b, and 9b) (29). These accessory proteins
are not homologous to any known proteins in any database.
The functions of these proteins are of particular interest for
understanding the pathogenesis of SARS-CoV, as the acces-
sory proteins of other coronaviruses contribute to in vivo
pathogenesis but are not essential for in vitro replication (5).
The goal of these experiments was to determine whether any
of the structural and accessory proteins of SARS-CoV are
interferon antagonists. Our experiments revealed that ORF 3b,
ORF 6, and nucleocapsid (N) proteins are all effective at pre-
venting the interferon response. All three of these proteins
have been shown to be expressed in tissue culture cells during
infection with SARS-CoV and in tissues obtained from SARS
patients (4). ORF 3b protein has a length of 154 amino acids
and is reported to localize to the nucleolus and the mitochon-
dria (30, 31). ORF 6 protein is 63 amino acids long and is
reported to localize to the endoplasmic reticulum (ER) (9). N
is a 422-amino-acid protein that is localized to the cytoplasm
(27). There are reports that N protein inhibits the progression
of the cell cycle and can activate the proinflammatory factor
cyclooxygenase-2 (24, 26).
The data presented here indicate that N protein inhibits
interferon production, while ORF 3b and ORF 6 proteins are
able to inhibit both interferon production and interferon sig-
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naling. IRF-3 activation is inhibited in cells that express ORF
3b, ORF 6, or N protein, and NF-B is inhibited in cells
expressing N protein. ORF 3b and ORF 6 proteins also effec-
tively inhibit expression of a reporter gene under the control of
a promoter containing an ISRE. STAT1 translocation is inhib-
ited in cells expressing ORF 6 protein but not ORF 3b or N
proteins, though none of these proteins reduce STAT1 phos-
phorylation. Taken together, our data indicate that SARS-
CoV encodes at least three interferon antagonists that in-
hibit different aspects of the interferon response. The
redundant functions of these three proteins probably aug-
ment the effective inhibition of the interferon response ob-
served during infection with SARS-CoV. This profound in-
hibition of the interferon response likely contributes to the
pathogenesis of SARS-CoV.
MATERIALS AND METHODS
Cells and plasmids. 293T and A549 cells were cultured in Dulbecco’s modified
Eagle medium (Invitrogen) containing 10% fetal bovine serum. The SARS-CoV
structural and accessory genes were amplified by RT-PCR from lysates of cells
infected with the Urbani strain of SARS Co-V and cloned into pCAGGS con-
structs with a tag encoding hemagglutinin (HA) on the C-terminal ends of the
proteins. Expression of the proteins was confirmed by Western blotting (data not
shown). An N gene which does not express ORF 9b protein was also cloned using
the upstream primer CGCGGAATTCACCATGTCTGATAACGGACCCCAA
TCA, which contains a mutation in the ATG start site of the ORF 9b gene but
does not change the amino acid in the N protein. pCAGGS-NS1, pCAGGS-
IRF-3, p55-CIB, NF-B-luc, Renilla luciferase, Nipah virus V, Nipah virus W,
PR8 strain influenza virus NS1, STAT1-green fluorescent protein (GFP), beta
interferon (IFN-)-red fluorescent protein (RFP)/CAT, and ISRE-GFP/CAT
(pHISG54-GFP/CAT) plasmids were described previously (12, 15, 20, 25).
Transfections. 293T cells were seeded in 24- or 6-well dishes for 24 h. Cells
were transfected with 100 ng or 500 ng per plasmid using 0.2 or 1 l of Lipo-
fectamine 2000, respectively, unless otherwise indicated.
NDV-GFP assay. A549 cells were seeded in 24-well dishes and transfected with
3 l of Lipofectamine 2000 and 1 g of the indicated plasmid in Fig. 1A. The
larger amounts of Lipofectamine 2000 and DNA were required to stimulate
interferon induction, as described previously (16). Cells were infected with New-
castle disease virus expressing green fluorescent protein (NDV-GFP) at a mul-
tiplicity of infection (MOI) of 10 at 24 h posttransfection and analyzed by
microscopy at 24 h postinfection.
Apoptosis analysis. 293T cells were seeded in 24-well dishes and transfected
with various GFP-tagged plasmids. At 24 h posttransfection, cells were analyzed
for the morphological changes associated with apoptosis using phase-contrast
and fluorescence microscopy. Cells were also harvested and analyzed for active
caspase-3 as described previously (13).
Confocal microscopy. 293T cells were seeded in 24-well dishes on coverslips.
At 24 h posttransfection, cells were fixed with 5% formaldehyde and permeab-
ilized with 1% Triton X-100. Cells were incubated with blocking buffer (phos-
phate-buffered saline [PBS], 0.05% Tween, 0.5% bovine serum albumin, 0.8%
glycine) for 5 min and then incubated with primary antibody at a dilution of 1:500
for 1 h at room temperature. Primary antibodies used were mouse anti-cyto-
chrome c (Pharmingen), rabbit anti-protein disulfide isomerase (PDI) (kind gift
from Domenico Tortorella), rabbit anti-phospho-STAT1 (Cell Signaling Tech-
nology), mouse anti-HA tag (Sigma), and mouse anti-Sendai virus antibodies
11F3 and 5F5 (1 g/ml) (15). Cells were washed three times with blocking buffer
and then incubated with either donkey anti-mouse immunoglobulin conjugated
with Alexa fluor 488, donkey anti-rabbit–Alexa fluor 594, donkey anti-mouse–
Alexa fluor 596, or BODIPY TR (all from Molecular Probes) at a dilution of
1:500 for 1 h. Cells were incubated with 4,6-diamidino-2-phenylindole-dihydro-
chloride (DAPI) (Molecular Probes) or Hoechst 33342 (Molecular Probes) for 5
min. Cells were washed three times, and coverslips were mounted on slides using
Aqua Polymount (Polysciences). Slides were analyzed by confocal microscopy
with a Zeiss LSM 510 Meta microscope.
Luciferase assays. 293T cells were seeded in 24-well dishes and transfected
with empty vector plasmid, plasmids encoding the SARS-CoV proteins, Renilla
luciferase plasmid, and pNF-B firefly luciferase plasmid or p55-CIB firefly
luciferase plasmid. For these transfections, 0.5 l of Fugene was used instead of
Lipofectamine 2000, since this amount of Fugene does not induce detectable
amounts of interferon. The NF-B-responsive promoter plasmid contains two
NF-B binding sites, and the p55-CIB plasmid contains three IRF-3 binding
sites. At 24 h posttransfection, cells were infected with Sendai virus at an MOI
of 10 for 24 h. Cells were harvested, lysed, and analyzed for firefly and Renilla
luciferase according to the manufacturer’s protocol (Promega). Values for the
samples were normalized using the Renilla luciferase values and expressed as
percentages of the value for the positive control.
Quantitative microscopy analysis. 293T cells were seeded in 24-well dishes
and transfected with the appropriate plasmids and either IFN-RFP or ISRE-
RFP plasmids. At 24 h posttransfection, cells were infected with Sendai virus or
treated with 3,000 U/ml human IFN- (Calbiochem). Cells were analyzed by
microscopy using an Olympus 1X70 microscope 24 h postinfection or posttreat-
ment. Images from three experiments were quantitated using Image J software
(NIH).
Western blots. 293T cells were seeded in 6-well dishes and transfected with
empty vector plasmid or plasmids encoding the SARS-CoV proteins. For analysis
of IRF-3, a plasmid encoding IRF-3 was also transfected in each sample. At 24 h
posttransfection, cells were infected with Sendai virus for 6 h (see Fig. 4B) or
serum starved for 4 h and treated with IFN- for 1 h (see Fig. 8A). Cells were
harvested and lysed in radioimmunoprecipitation assay buffer (PBS, 1% NP-40,
0.5% deoxycholate, 0.1% sodium dodecyl sulfate [SDS], and 1 mM EDTA)
supplemented with protease inhibitor cocktail (Complete; Roche) and phos-
phatase inhibitors (10 mM -glycerophosphate, 25 mM Na pyrophosphate, 50
mM NaF, 1 mM sodium orthovanadate). Lysates were spun down to remove
nuclei. The protein content was determined by a Bradford assay (Bio-Rad).
Aliquots of lysates representing equal amounts of protein were analyzed by
SDS-polyacrylamide gel electrophoresis. The proteins were transferred to a
nitrocellulose membrane and probed with anti-phospho-STAT1, recognizing
phosphorylation at tyrosine 701, or anti-phospho-IRF-3, recognizing phosphor-
ylation at serine 396 (Upstate), stripped with 0.2 N NaOH, and reprobed using
anti-total IRF-3 (Santa Cruz Biotechnology) or anti-total STAT1 (Cell Signaling
Technology).
RESULTS
Identification of SARS-CoV ORF 3b, ORF 6, and N proteins
as interferon antagonists. To determine whether the structural
or accessory proteins of SARS-CoV were interferon antago-
nists, the proteins were screened using an interferon bioassay.
In this assay, proteins are tested for their ability to complement
the growth of a recombinant NDV-GFP. NDV is ideal for this
assay, since it fails to replicate efficiently in the presence of a
type 1 interferon response, which is induced during liposome-
mediated plasmid transfection. For these experiments, A549
cells were transfected with plasmids expressing individual
SARS-CoV proteins, with empty vector plasmid as a negative
control, or with influenza virus NS1 protein as a positive con-
trol. At 24 h posttransfection, cells were infected with NDV-
GFP, and at 24 h postinfection, the cells were analyzed by
microscopy (Fig. 1). Cells infected with NDV-GFP fluoresce
green (shown as white), but cells transfected with empty vector
prior to infection did not display green fluorescence. Cells
transfected with influenza virus NS1 protein, a known inter-
feron antagonist, were green. Three SARS-CoV proteins—the
ORF 3b, ORF 6, and N proteins—rescued the growth of NDV-
GFP, indicating that they are potential interferon antagonists.
The other SARS-CoV proteins tested did not rescue the
growth of NDV-GFP. Expression of the SARS-CoV proteins is
shown in Fig. 1B. The proteins are expressed at different levels,
but there is no correlation between expression level and ability
to rescue the growth of NDV-GFP, since ORF 3b is not highly
expressed but does rescue the growth of NDV-GFP, while
other proteins, such as ORF 7b and 9b, are highly expressed
but do not rescue the growth of NDV-GFP.
The localization of the interferon antagonists was examined
(Fig. 2A to C). Cells were transfected with plasmids expressing
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ORF 3b (Fig. 2A), ORF 6 (Fig. 2B), or N (Fig. 2C) proteins for
24 h. Cells were fixed, permeabilized, and stained using mark-
ers for the ER, Golgi, mitochondria, and chromatin. ORF 3b
protein was localized to the nucleus, ORF 6 protein was local-
ized mainly to the ER and Golgi, and N protein was localized
diffusely throughout the cytoplasm but did not colocalize with
the cellular markers. There was no evidence of mitochondrial
localization of ORF 3b as had been previously reported (31).
The fact that the three proteins do not localize to the same
cellular compartments indicates that they may inhibit the in-
terferon response by different mechanisms. The ability of ORF
3b, ORF 6, and N proteins to induce apoptosis was also ana-
lyzed. Cells were transfected with plasmids expressing ORF 3b,
ORF 6, or N proteins for 24 h and analyzed for the morpho-
logical changes associated with apoptosis (Fig. 2D). ORF 7a
protein, which has been shown to induce apoptosis and inhibit
cellular gene expression, was used as a control. Cells expressing
ORF 3b, ORF 6, and N proteins have morphology similar to
that of cells expressing the negative control, GFP, while cells
expressing ORF 7a protein displayed changes associated with
apoptosis, such as rounding and shrinkage. To determine
whether the SARS-CoV proteins caused biochemical changes
associated with apoptosis, active caspase-3 was measured 24 h
posttransfection (Fig. 2E). Cells expressing ORF 7a protein
had abundant levels of active caspase-3, while cells expressing
ORF 3b, ORF 6, or N protein did not have levels of active
caspase-3 above that of the negative control. Previous reports
stated that N protein induces apoptosis in a small percentage
of cells when cells are serum starved but not when cells are
grown in serum (23, 32). Thus, ORF 3b, ORF 6, and N proteins
do not induce apoptosis and do not inhibit cellular gene ex-
pression (Fig. 2 and data not shown).
ORF 3b, ORF 6, and N proteins inhibit the synthesis of
IFN-. The mechanisms of the inhibition of the interferon
response by these three proteins were examined. One mecha-
nism by which viral proteins inhibit the interferon response is
by preventing expression from the interferon promoter. It has
been shown that interferon is not produced in cells infected
with SARS-CoV (22). To determine whether the antagonists
inhibit the induction of interferon, 293T cells were transfected
with a plasmid expressing RFP under the control of the IFN-
promoter. The cells were cotransfected with plasmids express-
ing the SARS-CoV proteins, with empty vector plasmid as a
negative control, or with a plasmid expressing influenza virus
NS1 protein as a positive control. At 24 h posttransfection,
cells were infected with Sendai virus to induce interferon syn-
thesis, and at 24 h postinfection, cells were analyzed by mi-
croscopy for red fluorescence (shown as white). Antagonists of
interferon induction prevent the expression of RFP.
Fluorescence images are shown in Fig. 3A, and the quanti-
tation of the RFP expression in three experiments is shown
Fig. 3B. The positive control, influenza virus NS1 protein,
dramatically reduces expression of RFP from the IFN- pro-
moter. SARS-CoV ORF 3b, ORF 6, and N proteins all reduce
FIG. 1. Identification of SARS-CoV ORF 3b, ORF 6, and N proteins as potential interferon antagonists. A. A549 cells were transfected with
either control plasmids or plasmids expressing HA-tagged SARS-CoV proteins. At 24 h posttransfection, cells were infected with NDV-GFP, which
grows in the presence of interferon antagonists. Images were obtained at 24 h postinfection using a 10 objective and are representative of three
experiments. B. A549 cells were transfected with plasmids expressing HA-tagged SARS-CoV proteins for 24 h, fixed, and analyzed for expression
of the SARS-CoV proteins using an antibody to the HA tag.
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expression of RFP (Fig. 3A and B). This indicates that the
three antagonists inhibit the induction of interferon. The N
gene actually encodes two proteins, N protein and ORF 9b
protein. A construct of the N gene was made which contained
a mutation in the start site of the ORF 9b protein but did not
alter the amino acid of the N protein. This plasmid, which
expresses N protein but not ORF 9b, was able to inhibit the
expression of RFP from the IFN- promoter as effectively as
the plasmid containing the unaltered N gene. This result, cou-
pled with the result in Fig. 1 showing that ORF 9b does not
rescue growth of NDV-GFP, indicate that N protein but not
ORF 9b is an interferon antagonist. Expression of Sendai virus
FIG. 2. Localization and apoptosis analysis of SARS-CoV ORF 3b, ORF 6, and N proteins. 293T cells were transfected with plasmids
expressing GFP-tagged ORF 3b (A), ORF 6 (B), or N (C) proteins for 24 h. Cells were fixed, permeabilized, and stained for either the Golgi using
BODIPY TR, the ER using an antibody to PDI, the mitochondria using an antibody to cytochrome c, or chromatin using a DAPI stain. Green
represents GFP-tagged protein, red represents the indicated organelle, and blue represents the chromatin. Cells were analyzed by confocal
microscopy using a 63 objective, and representative images are shown. D. 293T cells were transfected with GFP or plasmids expressing
GFP-tagged ORF 7a, ORF 3b, ORF 6, or N proteins for 24 h. Cells were analyzed by fluorescence and phase-contrast microscopy for
morphological changes associated with apoptosis. E. 293T cells were transfected for 24 h, harvested, lysed, and analyzed for caspase-3 activity.
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proteins in the presence of the SARS-CoV proteins is shown in
Fig. 3C. None of the SARS-CoV proteins inhibit expression of
Sendai virus proteins.
ORF 3b, ORF 6, and N proteins inhibit the function of
IRF-3, and N protein inhibits the function of NF-B. There are
several ways in which viruses inhibit the induction of inter-
feron. The transcription factor IRF-3 binds to the interferon
promoter when activated and has been shown to be necessary
for interferon induction. It was demonstrated that IRF-3 is
inhibited in cells infected with SARS-CoV (22). The ability of
IRF-3 to activate its DNA binding site was examined using a
plasmid construct containing a firefly luciferase gene under the
control of a promoter with three IRF-3 binding sites (55-CIB).
Cells were cotransfected with control plasmids or with plas-
mids expressing the SARS-CoV proteins, with the p55-CIB-
firefly luciferase plasmid, and with a plasmid that constitutively
expresses Renilla luciferase. The Renilla luciferase plasmid is
used to normalize expression levels of the samples. At 24 h
after transfection, cells were infected with Sendai virus to stim-
ulate interferon synthesis. Cells were harvested 24 h postinfec-
tion and analyzed for firefly and Renilla luciferase. Infection
with Sendai virus activated the 55-CIB promoter in cells trans-
fected with empty vector (Fig. 4A). The positive control, influ-
enza virus NS1 protein, inhibits expression from the 55-CIB
promoter. All three SARS-CoV proteins, ORF 3b, ORF 6, and
N, also inhibit expression of the 55-CIB promoter, indicating
that they prevent the activation of promoters requiring IRF-3
binding, such as interferon.
In order for IRF-3 to bind to promoters, IRF-3 must be
activated by phosphorylation. Phosphorylation of IRF-3 was
analyzed in cells transfected with a plasmid expressing IRF-3
and control plasmids or plasmids expressing SARS-CoV pro-
teins by Western blotting using an anti-phospho-IRF-3 anti-
body. At 24 h posttransfection, cells were infected with Sendai
virus for 6 h to stimulate IRF-3 phosphorylation. ORF 3b,
ORF 6, and N proteins all effectively inhibit phosphorylation of
IRF-3 (Fig. 4B). Quantitation of the Western blot revealed
that phosphorylation is inhibited by the SARS-CoV proteins,
but IRF-3 is not degraded.
Active IRF-3 translocates from the cytoplasm to the nucleus
in order to function as a transcription factor. Translocation of
IRF-3 was analyzed in cells transfected with control plasmids
or plasmids expressing SARS-CoV proteins and IRF-3–GFP.
At 24 h posttransfection, cells were infected with Sendai virus
for 8 h to stimulate IRF-3 translocation (Fig. 4C). IRF-3 is
present in the cytoplasm of mock-infected cells, while it is
FIG. 3. SARS-CoV ORF 3b, ORF 6, and N proteins inhibit pro-
duction of interferon. A. 293T cells were cotransfected with a plasmid
expressing red fluorescence protein under the control of the IFN-
promoter and empty vector plasmid, a plasmid expressing influenza
virus NS1, or plasmids expressing SARS-CoV proteins. At 24 h post-
transfection, cells were infected with Sendai virus to stimulate the
production of interferon. Images were captured 24 h postinfection
using a 10 objective. B. Images from three experiments described for
panel A were quantitated using Image J software. Data are averages
plus standard deviations for three experiments. C. Cells were trans-
fected with the indicated plasmids for 24 h and then infected with
Sendai virus for 24 h. Cells were fixed, permeabilized, and analyzed for
Sendai virus proteins using monoclonal antibodies to Sendai virus.
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present in the nuclei of Sendai virus-infected cells. All three
SARS-CoV proteins inhibit IRF-3 translocation. Thus, the
data in Fig. 4 indicate that the SARS-CoV proteins inhibit
IRF-3 function.
Another cellular component necessary for interferon synthe-
sis is NF-B. NF-B, like IRF-3, is a transcription factor acti-
vated after viral infection and binds to and activates the inter-
feron promoter. Activation of NF-B was examined using a
firefly luciferase construct under the control of an NF-B-
responsive promoter containing two NF-B binding sites. Cells
were cotransfected with control plasmids or with plasmids ex-
pressing the SARS-CoV proteins, with the pNF-B-firefly lu-
ciferase plasmid, and with the Renilla plasmid. At 24 h post-
transfection, cells were infected with Sendai virus, and at 24 h
postinfection, cells were harvested and analyzed for firefly and
Renilla luciferase. As expected, infection with Sendai activated
the promoter containing NF-B binding sites in cells trans-
fected with empty vector, and influenza virus NS1 protein
inhibited expression from this promoter (Fig. 5). SARS-CoV N
protein effectively inhibited activation of the promoter, while
ORF 6 protein was able to reduce expression of the NF-B-
responsive promoter to a lesser extent than N protein (P 
FIG. 4. SARS-CoV ORF 3b, ORF 6, and N proteins inhibit acti-
vation of IRF-3. A. 293T cells were cotransfected with the p55-CIB
promoter, which contains three IRF-3 binding sites, a plasmid that
constitutively expresses Renilla luciferase, and plasmids expressing
SARS-CoV proteins or the indicated control plasmids. Cells were
infected with Sendai virus 24 h posttransfection. Cells were harvested
at 24 h postinfection and analyzed for firefly and Renilla luciferase.
Data were normalized using the Renilla luciferase values. Data are
averages plus standard deviations for three experiments. A value of
100% represents approximately 10,000,000 firefly luciferase units(p55-
CIB) and 6,000,000 Renilla luciferase units. B. 293T cells were trans-
fected with the indicated plasmid and infected with Sendai virus for
6 h. Cells were harvested, and lysates were analyzed by Western blot-
ting using a phospho-IRF-3 antibody. Quantitations are given below
each band and are percentages of the value for the empty, infected
control. C. 293T cells were transfected with the indicated plasmids for
24 h and then infected with Sendai virus. Cells were fixed 8 h postin-
fection and analyzed by microscopy using an antibody that recognizes
the HA tag.
FIG. 5. N protein inhibits NF-B activation. 293T cells were co-
transfected with a plasmid expressing firefly luciferase under the con-
trol of an NF-B-responsive promoter containing two NF-B binding
sites, the Renilla luciferase plasmid, and the indicated plasmids. At
24 h posttransfection, cells were infected with Sendai virus. At 24 h
postinfection, cells were harvested and analyzed for firefly and Renilla
luciferase activities. Cells were normalized to the Renilla luciferase
control. Data are averages plus standard deviations for three experi-
ments. A value of 100% represents approximately 8,000,000 firefly
luciferase units and 6,000,000 Renilla luciferase units. The P values for
N and ORF 6 proteins were less than 0.05.
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0.05 for both). ORF 3b protein had little effect on the NF-B-
responsive promoter.
ORF 3b and ORF 6 proteins inhibit expression from an
ISRE promoter. While our data indicate that SARS-CoV ORF
3b, ORF 6, and N proteins inhibit the synthesis of interferon,
we also tested whether these proteins could inhibit the cellular
response to interferon (interferon signaling). Once interferon
is released from the cells, it binds to an interferon receptor,
and signaling occurs through a JAK/STAT pathway, resulting
in the activation of genes containing an ISRE in their promot-
ers. To determine whether ORF 3b, ORF 6, and N proteins
inhibit expression of genes containing an ISRE, cells were
cotransfected with the SARS-CoV proteins and with a plasmid
containing GFP under the control of an ISRE promoter, the
interferon-stimulated gene 54 promoter. At 24 h posttransfec-
tion, cells were either infected with Sendai virus or treated with
IFN-. Expression from the ISRE promoter after Sendai virus
infection requires both interferon synthesis and interferon sig-
naling, while expression from the ISRE promoter after treat-
ment with interferon only requires interferon signaling.
Representative images are shown in Fig. 6A and C, and quan-
titation of three experiments is shown in Fig. 6B and D. After
infection with Sendai virus, ORF 3b, ORF 6, and N proteins all
effectively inhibit expression from the ISRE promoter (Fig. 6A
and B), indicating that the proteins inhibit the interferon re-
sponse After treatment with IFN-, ORF 3b and ORF 6 pro-
teins inhibited expression from the ISRE promoter but N pro-
tein did not (Fig. 6C and D). Taken together with the data in
Fig. 3, these data indicate that N protein inhibits only inter-
feron synthesis, while ORF 3b and ORF 6 proteins inhibit both
interferon synthesis and interferon signaling.
ORF 6 protein inhibits the translocation of STAT1. Several
viruses express proteins that inhibit interferon signaling by
specifically targeting the transcription factor STAT1. In order
for STAT1 to be activated, STAT1 is phosphorylated and then
translocates to the nucleus. Translocation of STAT1 from the
cytoplasm to the nucleus was analyzed in cells expressing
SARS-CoV ORF 3b, ORF 6, and N proteins. Cells were co-
transfected with a STAT1-GFP fusion construct and plasmids
expressing ORF 3b, ORF 6, and N proteins. At 24 h posttrans-
fection, cells were treated with IFN-. Images were captured
1 h posttreatment, and representative images are shown in Fig.
7A. Treatment with interferon caused STAT1-GFP to trans-
locate to the nuclei of empty-vector-transfected cells (Fig. 7A).
Nipah virus proteins V and W were used as controls for viral
proteins that do and do not inhibit translocation of STAT1 to
the nucleus, respectively. SARS-CoV ORF 6 protein, but not
ORF 3b or N protein, was able to inhibit the translocation of
STAT1-GFP to the nucleus. A higher magnification of the
image of ORF 6 protein in cells transfected with STAT1-GFP
FIG. 6. Inhibition of a promoter containing an ISRE by SARS-CoV proteins. 293T cells were cotransfected with ISRE-GFP and the indicated
plasmid for 24 h. Cells were then infected with Sendai virus (A and B) or treated with IFN- (C and D) for 24 h and then analyzed by microscopy
using a 10 objective. Images were quantitated with ImageJ software (B and D). Data are averages plus standard deviations for three experiments.
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and treated with IFN- shows that ORF 6 protein does not
colocalize with STAT1, indicating that ORF 6 does not directly
interact with STAT1 (Fig. 7B).
To further analyze the activation of STAT1, phosphorylation
of STAT1 was analyzed in cells expressing the SARS-CoV
proteins. Cells were transfected for 24 h with empty vector
plasmid or plasmids expressing ORF 3b, ORF 6, or N proteins.
Cells were infected with Sendai virus for 6 h and then har-
vested and analyzed for STAT1 phosphorylation by Western
blotting using an antibody specific for phospho-STAT1. A rep-
resentative Western blot is shown in Fig. 8A. None of the
SARS-CoV proteins reduced STAT1 phosphorylation as ana-
lyzed by Western blotting. One possibility is that phosphory-
lation of the untransfected cells represents a large amount of
the phosphorylation observed in Fig. 8A, and thus any de-
crease in phosphorylation would be difficult to distinguish by
FIG. 7. ORF 6 protein inhibits translocation of STAT1 to the nu-
cleus. A and B. 293T cells were cotransfected with STAT1-GFP and
the indicated plasmids. At 24 h posttransfection, cells were treated
with IFN- for 1 h and then fixed and stained. Viral proteins were
visualized with an antibody to the HA tag, and DNA was visualized
using Hoechst 33342 stain. Green represents STAT1-GFP, red repre-
sents the viral protein, and blue represents DNA. Cells were analyzed
by confocal microscopy, and representative images are shown. All
images were obtained using a 63 objective; the images in panel B
were magnified using Zeiss confocal software.
FIG. 8. Analysis of STAT1 phosphorylation by SARS-CoV pro-
teins. A. 293T cells were transfected with the indicated plasmid for
24 h and then treated with IFN- for 1 h. Cells were harvested, and
lysates were analyzed by Western blot analysis using antibodies recog-
nizing the phospho- and total forms of STAT1. B. Cells were trans-
fected with the indicated plasmid and STAT-1 GFP for 24 h and then
treated with IFN- for 1 h. Cells were fixed, permeabilized, and ana-
lyzed for phospho-STAT1 by confocal microscopy using a 10 objec-
tive. Representative images are shown.
VOL. 81, 2007 SARS-CoV ORF 3b, ORF 6, AND N PROTEINS INHIBIT INTERFERON 555
Western blotting. To address this possibility, cells were co-
transfected with plasmids expressing the SARS-CoV proteins
and STAT1-GFP and treated with IFN-. Cells were fixed,
permeabilized, stained for phospho-STAT1, and analyzed by
confocal microscopy. Representative images are shown in Fig.
8B. High rates of transfection were observed in this experiment
as well as the other experiments described in this paper. Since
nearly all of the phosphorylated STAT1 is observed in trans-
fected cells, and nearly all of the transfected cells contain
phosphorylated STAT1, this confirms that none of the SARS-
CoV proteins inhibit STAT1 phosphorylation. There was no
difference in the amounts of STAT1 phosphorylation in the
ORF 3b, ORF 6, and N protein-expressing cells.
DISCUSSION
The inhibition of interferon is a common mechanism by
which viruses subvert the innate host response. Viral proteins
that target various aspects of the interferon pathways have
been identified (7). For influenza virus, a negative-sense seg-
mented RNA virus of the family Orthomyxoviridae, the inter-
feron antagonist has been identified as NS1 protein (6). NS1
inhibits the interferon response by preventing cells from de-
tecting the presence of the replicating influenza virus. NS1
binds and sequesters double-stranded RNA, a by-product of
viral replication that activates several cellular antiviral pro-
teins, such as protein kinase R and 2,5-oligo(A) synthetase
(2, 10, 14). Nipah virus, a negative-sense nonsegmented RNA
virus of the family Paramyxoviridae, encodes three proteins
which antagonize interferon by inhibiting the function of
STAT1 (16). Nipah virus V and P proteins act by retaining
STAT1 in the cytoplasm, while the W protein sequesters STAT1
in the nucleus, creating both a cytoplasmic and a nuclear
impediment for STAT1 (19, 20). Ebola virus, a negative-
sense nonsegmented RNA virus of the family Filoviridae,
encodes two proteins that antagonize different components
of the interferon pathway. Ebola virus protein VP35 inhibits
interferon by binding and sequestering double-stranded
RNA, while VP24 inhibits interferon by preventing the nu-
clear accumulation of activated STAT1 (1, 18). Interferon is
an important deterrent of SARS-CoV replication and dis-
ease in the mouse model, as SARS-CoV infection in STAT1
knockout but not wild-type animals is robust and associated
with prolonged viremia, extensive lung pathology, and spread to
multiple organs (11).
Our data indicate that SARS-CoV ORF 3b, ORF 6, and N
proteins all function as interferon antagonists (Fig. 1). All
three proteins inhibit the expression of IFN-, and further
examination revealed that all three proteins inhibited a key
protein necessary for the expression of IFN-, IRF-3 (Fig. 3
and 4). SARS-CoV ORF 3b, ORF 6, and N proteins all inhibit
activation of IRF-3 by phosphorylation and binding of IRF-3
to a promoter with IRF-3 binding sites. N protein dramatically
inhibited expression from an NF-B-responsive promoter,
while expression of ORF 6 protein resulted in a twofold inhi-
bition (Fig. 5). All three proteins were able to inhibit expres-
sion from an ISRE promoter after infection of Sendai virus,
while only ORF 3b and ORF 6 were able to inhibit expression
from the ISRE promoter after treatment with IFN- (Fig. 6).
This indicates that N protein inhibits the synthesis of inter-
feron but not interferon signaling. ORF 6 protein, but not
ORF 3b or N protein, inhibited the translocation of STAT1 to
the nucleus (Fig. 7). STAT1 is required for the activation of
ISRE promoters. Interestingly, ORF 6 protein did not prevent
the phosphorylation of STAT1 (Fig. 8). The interferon antag-
onists encoded by Nipah and Ebola viruses that inhibit STAT1
translocation do so by binding and inhibiting karyopherin-
alpha (3, 21). We are investigating the mechanism by which
ORF 6 protein blocks STAT1 localization to the nucleus as
well as the mechanism of interferon inhibition by all three
proteins. While the mechanisms of inhibition are unknown, it
is possible that ORF 3b interacts with nuclear transcription
factors necessary for the interferon response. ORF 6 may dis-
rupt ER/Golgi transport necessary for the interferon response,
and N protein may directly interact with double-stranded RNA
or interferon pathway components in the cytoplasm.
Like other highly pathogenic viruses, such as Nipah and
Ebola viruses, SARS-CoV encodes more than one protein that
is able to inhibit interferon. This may enhance the ability of the
viruses to inhibit the interferon response, since each viral an-
tagonist may inhibit interferon by 90 to 95% but not com-
pletely. Thus, encoding several proteins that are antagonists
increases the likelihood that the virus can completely inhibit
the interferon response. Viruses, such as Ebola virus and
SARS-CoV, that are able to target more than one part of the
interferon response are most likely to cause a severe inhibition
of interferon. This may contribute to their high pathogenicity.
Little is known about the function of ORF 3b and ORF 6
proteins. It has been shown that when mice are infected with a
related coronavirus, mouse hepatitis virus (MHV), containing
SARS-CoV ORF 6 protein, the mice die, in contrast to mice
infected with the normally nonlethal wild type MHV (17).
Although the mechanism of disease enhancement was not
identified, these data suggest that SARS-CoV ORF 6 encodes
important virulence determinants in SARS. Mutant SARS-
CoVs that lack one or both of the ORF 3b and ORF 6 genes
have been constructed. It has been reported that the deletion
viruses lacking ORF 3b and/or ORF 6 genes replicate to levels
similar to those of wild-type virus in several different tissue
culture cell types (29). There are also no differences between
cytopathogenesis of the deletion viruses and that of wild-type
virus. Thus, ORF 3b and ORF 6 do not have essential roles in
viral replication (29). In addition, the deletion viruses grew to
levels similar to those of wild-type virus in the lungs of BALB/c
mice at day 2 postinfection. This suggests that SARS-CoV is
able to inhibit the host interferon response without the ORF
3b and ORF 6 genes (29). This is consistent with the results
presented here, since it is likely that the N protein alone was
able to inhibit the interferon response sufficiently to allow viral
replication in the in vitro and in vivo systems studied thus far.
While it would be interesting to test a deletion virus lacking
ORF 3b, ORF 6, and N genes, it has been reported that a
functional N gene is required for efficient gene expression and
rescue of SARS-CoV and other coronaviruses (28). However,
the interferon antagonist domain of N may be separate and
distinct from the domain playing a required role in viral rep-
lication. Identification of the domain of N responsible for in-
terferon antagonism may make production of a reverse-engi-
neered SARS-CoV that allows replication but not IFN
blocking possible.
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The results presented here are especially significant since
interferon antagonists have not been previously identified for
any coronaviruses. Our data indicate that three viral proteins
likely contribute to the inhibition of IFN- and IRF-3 observed
in cells infected with SARS-CoV (22). It also remains a pos-
sibility that one or more of the nonstructural proteins encoded
by SARS-CoV also inhibit the interferon response. The SARS-
CoV proteome includes 14 additional replicase ORFs that
have not been evaluated for IFN antagonist activity. By encod-
ing at least three proteins that inhibit different aspects of the
interferon response, SARS-CoV has evolved to utilize different
mechanisms to undermine the host interferon response. Thus,
it is possible that other coronaviruses also encode proteins that
inhibit multiple levels of the interferon response.
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